SEC Form 4 · accession 0001179110-15-005348
PTC THERAPEUTICS, INC. · PTCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Elliott Boulding
Officer — Exec. VP and CLO
Period of report
Mar 20, 2015
Accepted (ET)
Mar 23, 2015 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070081
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 20, 2015 | S | 13,453 | $67.77 | D | 18,782 | D | |
| Common StockF3 | Mar 20, 2015 | S | 7,547 | $68.72 | D | 11,235 | D | |
| Common Stock | Mar 20, 2015 | S | 142 | $69.77 | D | 11,093 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on August 11, 2014 for the primary purposes of covering tax obligations associated with a restricted stock vesting event and diversification.
- F2This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.31 to $68.28 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.31 to $69.26 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.